Beta Drugs Limited (BETA) fundamentals
Beta Drugs Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as BETA (ISIN INE351Y01019). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Beta Drugs Limited does
Beta Drugs Limited is an India-based oncology medicine manufacturing company. The Company specializes in the intricate field of complex chemical synthesis for anti-cancer bulk drugs and finished dosages. The Company operates through one segment, Pharmaceuticals. Its product category includes cosmeceutical products and oncology products. The cosmeceutical products include La’Thrix, BACINOX, URTICALM, HUMIDA, NUSPLASH, UVIREX, ADVIBE, SENSIBAR, and RECAPRO. The oncology products include Temozad(Temozolomide), ADVIN(Vinorelbine), ADSIDE(Etoposide), ADRIB(Doxorubicin), ADCOV(Leucovorin calcium), ADPLATIN(Oxaliplatin), INOTAD(Irinotecan), ADCIST(Cisplatin), ADCARB(Carboplatin), ERLOTAD(Erlotinib), ADOXI(Docetaxel), AMGICIN(Gemcitabine), ADPAXIL(Paclitaxel), ADMIDE(Bicalutamide), and others. The Company's subsidiaries include Adley Lab Limited and Adley Formulations Private Limited.
Valuation and market data
| Last close | ₹2130.00 |
|---|---|
| Market capitalisation | ₹2,150 crore |
| Enterprise value | ₹2,140 crore |
| P/E (TTM) | 0.00 |
| Price to book | 10.91 |
| Price to sales (TTM) | 5.12 |
| Book value per share | ₹195.25 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Mon Nov 24 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹396 crore | ₹54 crore | ₹41 crore | 0.00 |
| Mar 2025 | ₹369 crore | ₹57 crore | ₹42 crore | 42.02 |
| Mar 2024 | ₹297 crore | ₹49 crore | ₹36 crore | 37.90 |
| Mar 2023 | ₹228 crore | ₹41 crore | ₹31 crore | 31.95 |
| Mar 2022 | ₹185 crore | ₹34 crore | ₹25 crore | 25.82 |
Figures are as reported (consolidated), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 59.1% |
|---|---|
| Foreign institutions (FII) | 1.0% |
| Mutual funds | 0.0% |
| Other domestic institutions | 6.2% |
| Retail and others | 33.6% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.